FDA Authorizes AstraZeneca’s COVID-19 Antibody Drug

Published on December 8, 2021

U.S. drug regulator Food and Drug Administration (FDA) said Wednesday it had authorized AstraZeneca’s antibody cocktail to prevent COVID-19 infections in individuals who have weak immune systems or a history of severe side effects from coronavirus vaccines.

Read Full Article (External Site)